



**Vical**

2011 Annual Report

## HIGHLIGHTS/PROJECTIONS

### Allovectin®

- Completed treatment and follow-up for final patients in Phase 3 pivotal trial in patients with metastatic melanoma
- Presented encouraging animal model data demonstrating a synergistic (more than additive) improvement in efficacy using a combination of Allovectin® with an anti-CTLA-4 antibody
- *Expect to release top-line data for primary endpoint (objective response rate at 24 weeks or more after randomization) and secondary endpoint (overall survival) in late 2012*

### TransVax™ CMV Vaccine

- Established exclusive worldwide license with Astellas Pharma Inc. to develop and commercialize TransVax™ for transplant recipients
- Published an article in The Lancet Infectious Diseases detailing results from the completed Phase 2 trial in hematopoietic stem cell transplant recipients
- *Expect Astellas to start Phase 3 trial in hematopoietic stem cell transplant recipients in the second half of 2012 and Phase 2 trial in solid organ transplant recipients shortly thereafter*

### CyMVectin™ CMV Vaccine

- Participated in a two-day public workshop on CMV vaccine development and evaluation sponsored by the U.S. Department of Health and Human Services
- *Exploring partnering opportunities*

### Herpes Simplex Vaccines

- Presented preclinical data for the company's Vaxfectin®-formulated vaccines against herpes simplex virus type 2 (HSV-2)
- *Advancing to Phase 1/2 trial in 2013*

CONDENSED FINANCIAL INFORMATION (Unaudited) <sup>1</sup>	2011	2010	2009
	<i>(in thousands, except per share data)</i>		
<b>Statement of Operations Data (for full year)</b>			
Revenues	\$ 30,018	\$ 8,711	\$ 12,686
Operating expenses	37,840	39,926	41,272
Loss from operations	(7,822)	(31,215)	(28,586)
Net investment income	539	830	28
Net loss	(7,283)	(30,385)	(28,558)
Net loss per common share (basic and diluted)	\$ (0.10)	\$ (0.51)	\$ (0.61)
Weighted average shares used in per share calculation	72,031	60,084	47,086
<b>Balance Sheet Data (at end of year)</b>			
Cash, cash equivalents, marketable securities, and long-term investments, including restricted	\$ 56,355	\$ 60,702	\$ 52,562
Working capital	47,096	49,874	38,424
Total assets	68,773	72,907	67,372
Long-term obligations, less current portion	1,964	2,211	2,380
Stockholders' equity	60,348	64,362	54,982

<sup>1</sup> The following tables summarize certain selected financial data derived from our audited financial statements. The information presented should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our audited financial statements and notes thereto appearing in the Annual Report on Form 10-K.

## Board of Directors

**R. Gordon Douglas, M.D.,  
Chairman**

Retired President  
Merck Vaccine Division

**Robert H. Campbell**

Retired Chairman and  
Chief Executive Officer  
Sunoco, Inc.

**Gary A. Lyons**

Former President and  
Chief Executive Officer  
Neurocrine Biosciences

**Robert C. Merton, Ph.D.**

School of Management  
Distinguished Professor of  
Finance

MIT Sloan School of  
Management

**Vijay B. Samant**

President and  
Chief Executive Officer  
Vical Incorporated

## Executives

**Vijay B. Samant**

President and  
Chief Executive Officer

**Jill M. Broadfoot**

Senior Vice President,  
Chief Financial Officer and  
Secretary

**Alain P. Rolland, Pharm. D., Ph.D.**

Executive Vice President,  
Product Development

**Igor P. Bilinsky, Ph.D.**

Senior Vice President,  
Corporate Development

**Richard T. Kenney, M.D.**

Senior Vice President,  
Clinical Development

**Larry R. Smith, Ph.D.**

Vice President,  
Vaccine Research

## Contact

**Vical Incorporated**

10390 Pacific Center Court  
San Diego, CA 92121-4340

Tel: (858) 646-1100

Fax: (858) 646-1150

Email: [info@vical.com](mailto:info@vical.com)

Website: [www.vical.com](http://www.vical.com)

## Transfer Agent

**Computershare**

480 Washington Boulevard  
Jersey City, New Jersey 07310

Tel: (888) 835-2721

TDD for Hearing Impaired:  
(800) 231-5469

Foreign Shareowners:

(201) 680-6578

TDD for Foreign Shareowners:

(201) 680-6610

Website: [www.bnymellon.com/  
shareowner/equityaccess](http://www.bnymellon.com/shareowner/equityaccess)

## Attorneys

**Cooley LLP**

4401 Eastgate Mall  
San Diego, CA 92121-9109

Tel: (858) 550-6000

Website: [www.cooley.com](http://www.cooley.com)

## Independent Registered Public Accounting Firm

**Ernst & Young LLP**

4370 La Jolla Village Drive  
Suite 500

San Diego, CA 92122-1249

Tel: (858) 535-7200

Website: [www.ey.com](http://www.ey.com)

## Annual Meeting of Stockholders

**Hilton Times Square**  
234 West 42<sup>nd</sup> Street  
New York, NY 10036

Thursday, May 24, 2012

8:00 a.m.

Directions: (212) 840-8222

## Corporate Information

Vical's common stock is traded on the Nasdaq Global Market under the symbol VICAL.

Vical's Annual Report on Form 10-K contains additional information about our business, including our full financial statements and related notes, and is therefore an integral part of this report. In addition, this report contains statements that discuss our future expectations, contain projections of our results of operations and financial condition and include other forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our actual results may differ significantly and materially from those expressed in these forward-looking statements as a result of risks and uncertainties, including those detailed in our Annual Report on Form 10-K. We disclaim any intent or obligation to update these forward-looking statements, and you should not unduly rely on them.

## SEC Form 10-K

A copy of the exhibits to Vical's Annual Report on Form 10-K filed with the Securities and Exchange Commission is available, upon payment of our reasonable expenses in furnishing such exhibits, upon written request to:

Investor Relations  
Vical Incorporated  
10390 Pacific Center Court  
San Diego, CA 92121-4340

